Roivant Sciences Ltd.
ROIV
$11.40
$0.3152.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.05M | 30.50M | 37.05M | 36.22M | 32.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.05M | 30.50M | 37.05M | 36.22M | 32.71M |
| Cost of Revenue | 545.52M | 506.43M | 466.52M | 440.13M | 431.61M |
| Gross Profit | -516.47M | -475.93M | -429.48M | -403.91M | -398.90M |
| SG&A Expenses | 570.21M | 442.22M | 410.85M | 382.24M | 380.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.12B | 948.65M | 877.37M | 822.37M | 812.14M |
| Operating Income | -1.09B | -918.15M | -840.32M | -786.15M | -779.43M |
| Income Before Tax | -681.59M | -579.27M | 4.81B | 4.79B | 4.57B |
| Income Tax Expenses | 48.17M | -6.92M | 41.01M | 31.79M | 21.50M |
| Earnings from Continuing Operations | -729.76 | -572.35 | 4.77K | 4.76K | 4.55K |
| Earnings from Discontinued Operations | 373.03M | 285.49M | -100.04M | -143.44M | -315.15M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 184.75M | 170.23M | 142.45M | 119.50M | 117.72M |
| Net Income | -171.98M | -116.62M | 4.81B | 4.74B | 4.35B |
| EBIT | -1.09B | -918.15M | -840.32M | -786.15M | -779.43M |
| EBITDA | -1.07B | -895.55M | -817.15M | -759.37M | -751.69M |
| EPS Basic | -0.24 | -0.14 | 5.99 | 5.91 | 5.40 |
| Normalized Basic EPS | -0.46 | -0.31 | -0.30 | -0.33 | -0.41 |
| EPS Diluted | -0.25 | -0.15 | 5.65 | 5.57 | 5.06 |
| Normalized Diluted EPS | -0.46 | -0.31 | -0.29 | -0.33 | -0.40 |
| Average Basic Shares Outstanding | 2.90B | 3.00B | 3.07B | 3.11B | 3.13B |
| Average Diluted Shares Outstanding | 2.90B | 3.00B | 3.12B | 3.15B | 3.18B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |